1493-P: Harnessing Continuing Education to Improve Understanding of Amylin's Role in Obesity among Specialists and Primary Care Providers

Introduction and Objective: As understanding of obesity pathophysiology expands, clinicians across care settings face challenges in keeping pace with newly identified biological pathways and rapidly evolving clinical evidence. Consequently, they have limited knowledge and confidence related to novel mechanisms, including amylin-based therapies for obesity. Methods: An online continuing education (CE) activity launched in August 2025 featuring a 3-part text-based series describing the role of amylin in obesity regulation and emerging therapeutic strategies. Clinician knowledge and confidence regarding amylin biology and emerging amylin-based therapies for obesity were assessed via pre-, intra-, and post-test questioning. Results: A total of 339 clinicians have participated, including specialists in endocrinology, diabetes, and metabolism and primary care providers (PCPs). Overall knowledge of the mechanisms and clinical data for emerging amylin-based therapies increased by 42%. Pre-learning, 50% of specialists and 47% of PCPs had knowledge of amylin’s impact on satiety, increasing post-learning to 96% and 95%, respectively. Knowledge of emerging clinical evidence for amylin-based therapies increased from 6% to 24% among specialists and from 16% to 41% among PCPs. At baseline, just 19% of specialists and 15% of PCPs were confident in their understanding of amylin-based therapies for obesity, while post-learning, specialists were 23% and PCPs were 34% more confident in evaluating amylin-based therapies. Additionally, 69% of specialists and 85% of PCPs reported increased likelihood of using amylin-based therapies once approved. Conclusion: This CE program improved knowledge and confidence of emerging science related to amylin and novel obesity therapies among both specialists and PCPs. While knowledge of amylin-based therapies remains an ongoing area of need, CE is valuable for aligning understanding of emerging mechanisms across care settings as obesity therapeutics continue to evolve. Disclosure S. Johnson: None. H. Collier: None. J.L. Frederick: None. S. Persaud: None. K. Robinson: None. Funding Novo Nordisk Inc. (96301413)